Neuroone Medical Technologies (NMTC) Capital Expenditures (2019 - 2026)

Neuroone Medical Technologies (NMTC) has reported Capital Expenditures for 8 consecutive years, with $19659.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures fell 54.86% year-over-year to $19659.0; the trailing twelve-month figure through Jun 2026 stood at $109536.0 (up 1.38% YoY), and the FY2025 full-year result was $81742.0, down 31.99% from the prior year.
• Capital Expenditures eased to $19659.0 in Q2 2026 per NMTC's latest filing, from $38516.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $175694.0 in Q1 2023 and bottomed at $3171.0 in Q1 2025.
• Historically, Capital Expenditures has averaged $49928.9 across 5 years, with a median of $37823.5 in 2023.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures plunged 89.89% in 2025, then surged 1114.63% in 2026.
• Over 5 years, Capital Expenditures stood at $11512.0 in 2022, then surged by 222.54% to $37131.0 in 2023, then tumbled by 34.24% to $24416.0 in 2024, then surged by 66.92% to $40754.0 in 2025, then sank by 51.76% to $19659.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $19659.0, $38516.0, and $40754.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.